Ultimately, a paradigm shift toward proactive and patient-centered care is crucial for addressing this global health challenge, with a focus on preventing disease progression, optimizing treatment outcomes, and enhancing patient quality of life. Emerging therapies for DKD, including SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 receptor agonists, are transforming treatment by offering significant renal and cardiovascular benefits. The gene discussed is SLC5A2; the disease is diabetic kidney disease.